Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (603896.SS)
CNY 22.22
(0.63%)
CNY 22.22
(0.63%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1 Billion CNY | 5.51% |
| 2022 | 950.66 Million CNY | 177.64% |
| 2021 | 342.41 Million CNY | -8.27% |
| 2020 | 373.27 Million CNY | 121.77% |
| 2019 | 168.31 Million CNY | -18.61% |
| 2018 | 206.78 Million CNY | 265.38% |
| 2017 | 56.59 Million CNY | -67.69% |
| 2016 | 175.16 Million CNY | -26.21% |
| 2015 | 237.37 Million CNY | 31.56% |
| 2014 | 180.42 Million CNY | 64.24% |
| 2013 | 109.85 Million CNY | -19.01% |
| 2012 | 135.63 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 849.64 Million CNY | -12.08% |
| 2024 Q3 | 822.58 Million CNY | -3.19% |
| 2024 Q1 | 966.39 Million CNY | -3.66% |
| 2023 Q2 | 1.01 Billion CNY | 0.59% |
| 2023 Q1 | 1.01 Billion CNY | 6.34% |
| 2023 FY | 1 Billion CNY | 5.51% |
| 2023 Q4 | 1 Billion CNY | 9.2% |
| 2023 Q3 | 918.57 Million CNY | -9.67% |
| 2022 Q1 | 348.7 Million CNY | 1.84% |
| 2022 FY | 950.66 Million CNY | 177.64% |
| 2022 Q4 | 950.66 Million CNY | 73.73% |
| 2022 Q3 | 547.19 Million CNY | 36.82% |
| 2022 Q2 | 399.94 Million CNY | 14.69% |
| 2021 Q4 | 342.41 Million CNY | 7.16% |
| 2021 Q2 | 377.87 Million CNY | -3.75% |
| 2021 Q3 | 319.53 Million CNY | -15.44% |
| 2021 Q1 | 392.59 Million CNY | 5.17% |
| 2021 FY | 342.41 Million CNY | -8.27% |
| 2020 Q4 | 373.27 Million CNY | -19.87% |
| 2020 Q1 | 177.45 Million CNY | 5.43% |
| 2020 Q2 | 466.05 Million CNY | 162.63% |
| 2020 FY | 373.27 Million CNY | 121.77% |
| 2020 Q3 | 465.83 Million CNY | -0.05% |
| 2019 Q1 | 204.34 Million CNY | -1.18% |
| 2019 Q2 | 174.98 Million CNY | -14.36% |
| 2019 Q3 | 166.17 Million CNY | -5.04% |
| 2019 FY | 168.31 Million CNY | -18.61% |
| 2019 Q4 | 168.31 Million CNY | 1.29% |
| 2018 Q2 | 206.3 Million CNY | 152.76% |
| 2018 FY | 206.78 Million CNY | 265.38% |
| 2018 Q4 | 206.78 Million CNY | 28.09% |
| 2018 Q1 | 81.62 Million CNY | 44.22% |
| 2018 Q3 | 161.43 Million CNY | -21.75% |
| 2017 Q2 | 66.84 Million CNY | -57.9% |
| 2017 Q3 | 51.96 Million CNY | -22.25% |
| 2017 Q4 | 56.59 Million CNY | 8.9% |
| 2017 FY | 56.59 Million CNY | -67.69% |
| 2017 Q1 | 158.75 Million CNY | -9.37% |
| 2016 Q4 | 175.16 Million CNY | 0.0% |
| 2016 Q2 | 216.54 Million CNY | 0.0% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 FY | 175.16 Million CNY | -26.21% |
| 2015 FY | 237.37 Million CNY | 31.56% |
| 2014 FY | 180.42 Million CNY | 64.24% |
| 2013 FY | 109.85 Million CNY | -19.01% |
| 2012 FY | 135.63 Million CNY | 0.0% |